Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 1—January 2008

Dispatch

Adamantane-Resistant Influenza Infection During the 2004–05 Season

Mahbubur Rahman*1, Rick A. Bright†2, Burney A. Kieke*, James G. Donahue*, Robert T. Greenlee*, Mary Vandermause*, Amanda Balish†, Angela Foust†, Nancy J. Cox†, Alexander I. Klimov†, David K. Shay†, and Edward A. Belongia*Comments to Author 
Author affiliations: *Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 2

Demographic features of patients with adamantine-resistant or -susceptible influenza A, 2004–05 season*

VariableNo. (%) resistant isolates, n = 72No. (%) susceptible isolates, n = 80Unadjusted prevalence ratio (95% CI)Adjusted prevalence ratio (95% CI)
Age and high-risk status†
6–23 mo without high risk20 (74.1)7 (25.9)2.0 (1.3–3.0)2.1 (1.4–3.1)
6–23 mo with high risk3 (50.0)3 (50.0)1.3 (0.6–3.2)1.4 (0.5–3.5)
2–17 y with high risk8 (61.5)5 (38.5)1.7 (0.9–2.9)1.4 (0.8–2.4)
18–49 y with high risk7 (36.8)12 (63.2)1.0 (0.5–2.0)0.9 (0.5–1.9)
50–64 y with high risk8 (38.1)13 (61.9)1.0 (0.5–2.0)1.0 (0.6–1.9)
>65 y without high risk7 (46.7)8 (53.3)1.3 (0.7–2.4)1.2 (0.7–2.3)
>65 y with high risk
19 (37.2)
32 (62.8)
Referent group
Referent group
Sex
Male37 (50.7)36 (49.3)1.1 (0.8–1.6)1.1 (0.8–1.5)
Female
35 (44.3)
44 (55.7)
Referent group
Referent group
Dates of clinical encounter
2005 Jan 3–2310 (47.6)11 (52.4)0.9 (0.5–1.4)0.9 (0.5–1.5)
2005 Jan 24–Feb 1344 (55.0)36 (45.0)Referent periodReferent period
2005 Feb 14–Mar 615 (35.7)27 (64.3)0.6 (0.4–1.0)0.6 (0.4–1.0)
2005 Mar 7–25
3 (33.3)
6 (66.7)
0.6 (0.2–1.6)
0.5 (0.2–1.3)
Received 2004–05 influenza vaccine?
Yes45 (42.9)60 (57.1)0.7 (0.5–1.0)0.8 (0.6–1.1)
No27 (57.4)20 (42.6)Referent groupReferent group

*CI, confidence interval.
†For the multivariate model, a composite variable was created based on age and the presence or absence of a high-risk medical condition as defined by Advisory Committee on Immunization Practices criteria.

Main Article

1Current affiliation: University of Texas Medical Branch, Galveston, Texas, USA

2Current affiliation: Novavax, Malvern, Pennsylvania, USA

TOP